There are currently 40 active clinical trials seeking participants for Solid Tumors research studies. The states with the highest number of trials for Solid Tumors participants are Texas, California, New York and Florida.
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
NCT06205706
Recruiting
The goal of this first in human clinical trial is to test BI-1910 administered as single agent and in combination with pembrolizumab in subjects with advanced/metastatic solid tumors whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1910 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials Participants will receive infusions of BI-1910 alone or combination with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: Yale Cancer Center, New Haven, Connecticut +11 locations
Conditions: Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma
Register for Updates
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Loma Linda University Medical Center, Loma Linda, California +90 locations
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472
Recruiting
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2023
Locations: Mary Crowley Cancer Research, Dallas, Texas +4 locations
Conditions: Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation, Small Cell Lung Cancer, SCLC
Register for Updates
Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
NCT04692662
Recruiting
Background: People with advanced cancer are usually treated with surgery, radiation, immunotherapy drugs, or chemotherapy drugs. Talazoparib is a type of drug called a PARP inhibitor. It prevents DNA repair and has shown anticancer activity in early clinical trials. Researchers want to learn more about how it works in different types of patients. Objective: To find out how talazoparib works in tumor cells and if it works differently in people who have or have not already been treated with ano... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2021
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Solid Tumors
Register for Updates